WO1995013294A1 - Cytokines from natural killer or t cells - Google Patents
Cytokines from natural killer or t cells Download PDFInfo
- Publication number
- WO1995013294A1 WO1995013294A1 PCT/US1994/012835 US9412835W WO9513294A1 WO 1995013294 A1 WO1995013294 A1 WO 1995013294A1 US 9412835 W US9412835 W US 9412835W WO 9513294 A1 WO9513294 A1 WO 9513294A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- free preparation
- secretion
- ifn
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the invention is in the field of cytokines. More specifically it is in the field of cytokines which potently induce antibody secretion by activated animal B cells.
- Cytokines are proteinaceous substances or protein factors whose activity is derived from T cells or Natural Killer (NK) cells. They serve as the
- the specificity of the cytokines has raised great hopes for their use and products derived therefrom in the prevention and therapy of abnormal health
- a second object of this invention is to provide a cytokine which can potently induce antibody secretion by activated animal B cells.
- cytokine production by T cells has activity which is inhibited by treatment with a proteolytic enzyme; has activity which is optimal within 3 to 5 hours after activation of the T cell; has detectable activity at dilution levels as low as 1:3000 and operates as a late acting factor required to induce proliferated B cells to mature into antibody secreting cells. It appears that the similarity between the cytokines discovered by applicants as being derived from NK cells or T cells range from
- a method of producing a cytokine preparation is provided,
- FACS fluorescence-activated cell sorting
- ELISA enzyme-linked Immunosorbent Assay
- Cytokines prepared in accordance with this invention are derived from mammalian cells, including humans, and can be used generally to stimulate the immune system in immunocompromised hosts. Their utility extends to such areas as adjuvants for
- AIDS autoimmune deficiency syndrome
- ARC AIDS related complex
- an antagonist or monoclonal antibody to neutralize the cytokine can be made or uniquely identifying and isolating its receptor on the surface of the B cell would be useful in the modulation of antibody production.
- the identification of the receptor on the surface of the B cell can be utilized to create an antagonist (soluble receptor to prevent binding of the cytokine to the receptor.
- cytokines may be used alone or in combination with other cytokines (i.e., as pharmaceutical cocktail) to stimulate antibody production.
- Figure 1 depicts total, RBC-lysed, spleen cells that were stained with FITC-labelled anti-CD3 mAb (2C11) and phycoerythrin-labelled polyclonal goat anti-mouse IgM (left upper panel [unsorted]).
- B cells are IgM + CD3-
- T cells are IgM-CD3 +
- non-B, non-T cells are IgM-CD3-.
- Re-analyses of sorted cells are displayed in right upper panel (B cells), left lower panel (T cells), and right lower panel (non-B, non-T cells).
- Figure 2 shows B e and B sp cells that were cultured at 1.25 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml) and/or IL-2 (150 U/ml) in the absence or presence of 10% non-B, non-T cells (IgM-CD3-).
- SN was harvested for determination of secreted IgM concentrations by ELISA.
- Figure 3 shows B e cells that were treated for 30 min at 4°C with a polyclonal rabbit anti-AsGm-1 antisera (150 mg/ml) followed by a 30 min incubation at 37°C in a complement-containing solution in order to lyse AsGm-1 + cells.
- B e cells with or without anti-AsGm-1 antibody treatment were cultured at 2 ⁇ 10 5 cells/ml in the presence or absence of ⁇ -dex (3 ng/ml), and/or IL-1 (100 U/ml) plus IL-2 (150 U/ml).
- Figure 4 depicts a pure population of activated NK cells were established by IL-2 stimulation, in vitro, of spleen cells derived from scid mice (see
- FITC-labelled anti-Ia k mAb (Y3-P; control mAb-i.e. scid mutation established on BALB/c background [Ia d ]).
- Each flow cytometric tracing represents the fluorescence pattern of 10,000 viable cells.
- Figure 5 shows B sp cells that were cultured at 1.25 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml) and/or IL-1 (100 U/ml) plus IL-2 (150 U/ml) in the absence or presence of 10% sort-purified splenic non-B, non-T cells
- FIG. 6 shows B sp cells that were cultured at 1.5 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml), IL-1 (150 U/ml), plus IL-2 (150 U/ml) in the presence of increasing numbers of in vitro-generated pure NK cells (0-80% of B sp cell numbers). 7 days after initiation of culture, SN was harvested for determination of secreted IgM
- FIG. 7 shows B sp cells that were cultured at 1.5 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml), IL-1 (100 U/ml) plus IL-2 (150 U/ml) in the absence or presence of varying concentrations of NK-BMF (10-50% v/v).
- FIG. 8 shows B 5p cells that were cultured at 1.25 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml), IL-1 (150 U/ml) plus IL-2 (150 U/ml) in the absence or presence of SN obtained 24 h after activation, with plate-bound anti-CD3 mAb (2C11), of the following CD4 + Th1 clones: (1) RA1 (1:0% SN v/v), (2) RA5 (1.0% SN v/v), (3) RA8 (1.0% SN v/v), (4) RC5 (1.0% SN v/v), and (5) RC9 (2.5% SN v/v). SN was harvested for determination of secreted IgM concentrations by ELISA.
- Figure 9 shows B sp cells that were cultured at 1.25 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml), IL-1 (150 U/ml), plus IL-2 (150 U/ml) in the absence or presence of varying, final concentrations of SN (0.01-1.0% v/v) from anti-CD3-activated Th1 clones (see Fig 8). SN was harvested for determination of secreted IgM
- FIG. 10 shows a 24 h SN from anti-CD3-activated RA5 Th1 clone (T-BMF) was incubated at 37°C in the presence (RA5-SN-PK) or absence (RA5-SN-Ctrl) of proteinase K.
- B sp cells were cultured at 1.25 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml), IL-1 (150 U/ml) plus IL-2 (150 U/ml) in the absence or presence of either RA5-SN-PK (1.0% v/v) or RA5-SN-Ctrl (1.0% v/v).
- RA5-SN-PK (1.0% v/v) and RA5-SN-Ctrl (1.0% v/v) were added to B sp cell cultures activated with ⁇ -dex (3 ng/ml) plus IL-5 (150 U/ml).
- SN was harvested for determination of secreted IgM concentrations by ELISA.
- Figure 11 shows a 24 h SN from the anti-CD3-activated RA5 Th1 clone (T-BMF) or SN from unactivated resting RA5 cells (Control SN) was tested in an IL-6-specific sandwich ELISA. Recombinant IL-6 was used to generate a standard curve.
- Figure 12 shows B sp cells that were cultured at 1.25 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml), IL-1 (150 U/ml) plus IL-2 (150 U/ml) in the absence or presence of varying concentrations of anti-CD3-activated RA5 SN (0.001-1.0% v/v) obtained at various time points after anti-CD3 activation (0-24h). SN was harvested for determination of secreted IgM concentrations by ELISA.
- Figure 13 shows B sp cells that were cultured at 1.25 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml), IL-1 (150 U/ml) Plus IL-2 (150 U/ml).
- T-BMF 1% v/v of RA5 SN was additionally added to replicate cultures on different days (day 0-6).
- SN was harvested from all experimental groups 6 days after initiation of culture for
- the active substance is a protein whose activity is derived from T cells which potently induce antibody secretion by activated animal B cells, said substance:
- a. is resistant to neutralization by monoclonal antibodies or receptor antagonists against cytokines produced by activated T cells;
- b. has Ig secretion activity which is not mimicked by the addition of T cell cytokines in the absence of said cell-free preparation; c. can be produced by activation of the T cell through the T cell receptor signalling pathway which induces cytokine production by T cells;
- d. has activity which is inhibited by treatment with a proteolytic enzyme
- e. has activity which is optimal within 3 to 5 hours after activation of the T cell; f. has detectable activity at dilution levels as low as 1:3000; and
- Interleukin-4 Interleukin-6 ; Interleukin-10 ; TNF- ⁇ ; IFN- ⁇ ; IFN- ⁇ and TNF- ⁇ ; IFN- ⁇ ; IFN- ⁇ and IFN- ⁇ ; IFN- ⁇ and TNF- ⁇ ; IFN- ⁇ , IFN- ⁇ and TNF- ⁇ ; GM-CSF; and TGF- ⁇ 1.
- Interleukin-2 wherein said B cells are at least 98.5 percent purified through fluorescence-activated cell sorting (FACS);
- cytokines which are known to play a role in B cell activation and differentiation.
- the first activity was identified in culture supernatants from pure populations of in vitro-generated IL-2-activated murine natural killer (NK) cells.
- the second activity was identified in the culture supernatants of a panel of anti-CD3-activated murine CD4 + T lymphocyte clones. While these two activities are functionally similar, they could represent distinct molecules, studies to identify the murine BMF from one of the CD4 + T cell clones are currently underway.
- mice Female DBA/2 mice were obtained from the National Cancer Institute (Frederick, MD) and were used at 7-10 weeks of age. The experiments were conducted according to the principles set forth in the Guide for the Care and Use of Laboratory Animals, Institute of Animal Resources, National Research Council, Department of Health, Education, and Welfare. Publ No. (National Institutes of Health) 78-23. Culture medium.
- RPMI 1640 Biofluids, Rockville, MD supplemented with 10% fetal bovine serum (Gibco Laboratories, Grand Island, N.Y.), L-glutamine (2 mM), 2-mercaptoethanol (0.05 mM), penicillin (50 mg/ml), streptomycin (50 ⁇ g/ml), and gentamicin (50 mg/ml) were used for culturing cells.
- Reagents. ⁇ -dex was prepared by conjugation of H ⁇ a /1 (monoclonal mouse IgG2b (b allotype) anti-mouse IgD (a allotype) to a high molecular weight dextran (2 ⁇ 10 6 M.W.). Approximately 6 H ⁇ a /1 were conjugated to each dextran molecule.
- LPS W extracted from Libco Laboratories, Grand Island, N.Y.
- 2-mercaptoethanol 0.05 mM
- penicillin 50 mg/ml
- streptomycin 50
- Escherichia coli 0111:B4 was obtained from Difco Laboratories, Inc. (Detroit, MI) and was used at 20 mg/ml in all experiments. Affinity-purified,
- phycoerythrin-labelled polyclonal goat anti-mouse IgM was obtained from Southern Biotechnology Associates (Birmingham, AL).
- FITC-labelled monoclonal hamster IgG anti-CD3e (2C11) monoclonal antibody (mAb) was obtained from Pharmingen (San Diego, CA).
- Polyclonal rabbit anti-AsGm-l was obtained from Wako (Osaka, Japan).
- Murine recombinant (r)IL-1 was a gift from Dr.
- Murine rIL-2 was a gift from-Dr. Maurice Gately (Hoffman LaRoche,
- Murine rIL-5 was a gift from Dr. Richard Hodes (NIH, Bethesda, MD). Preparation and culture of B cells. Enriched populations of B cells were obtained from spleen cells from which T cells were eliminated by treatment with monoclonal rat IgM anti-Thy-1 (H013-4), rat IgG2b anti-CD4 (GK1.5), and rat IgG2b anti-CD8 (2.43), followed by mouse anti-rat Igk (MAR 18.5) and complement. Cells were then fractionated into high and low density populations by centrifugation over a
- Percoll gradient (Pharmacia, Piscataway, NJ) consisting of 70, 65, 60, and 50% Percoll solutions (with
- B cells obtained in this way were referred to as "B cell-enriched" (B e ) cells.
- B e B cell-enriched cells. This cell population is also known to contain small numbers of NK cells, macrophages, mast cells, and cells of the granulocytic series.
- B e cells (10 7 cells/ml) were incubated in "cytotoxicity medium” (CM) (RPMI + 2.5 mM Hepes + 0.3% BSA) with anti-AsGm-1 antibody (150 mg/ml final concentration) at 4°C for 1 h. Cells were then washed once in cold CM and
- CM containing a 1/10 dilution of rabbit complement (Pel-Freeze, Brown Deer, Wisconsin) at 37°C for 1 h. Cells were then washed and resuspended in medium for further use. Functional assays were carried out in 96-well flat-bottom Costar plates (Costar, Cambridge, MA). Cultured cells were incubated at 37°C in a humidified atmosphere containing 6% CO 2 . Establishment of NK cell cultures. Spleen cells from CB-17 SCID mice, obtained from NCI (Frederick, MD), were cultured in medium at 1 ⁇ 10 7 /ml in the presence of 500 U/ml of rhIL-2.
- NK cells were first treated with anti-Thy-1, anti-CD4, and anti-CD8 + complement as a precaution against the possible presence of small numbers of T cells resulting from "leakiness" in the SCID mutation.
- NK cells were maintained by splitting them 1:2 into fresh medium + 500 U/ml of IL-2 every 2-3 days. Cells were used for experiments beginning -7-10 days after establishment of culture. Such cells were monitored by flow cytometry to confirm the absence of CD3 + (T) cells.
- T CD3 +
- NK-BMF NK-BMF was prepared in two basic ways: (1) In vitro-maintained, IL-2-activated NK cells were washed 3x and recultured at 1.0 ⁇ 10 5 cells/ml in the presence of IL-2 (500 U/ml). 24 h later cell-free culture SN was harvested, aliquotted, and stored at -20oC until used (2) In vitro-maintained, IL-2-activated NK cells were washed 3x and recultured at 1.0 ⁇ 10 5 cells/ml in the presence of 5 ⁇ 10 5 B e cells/ml, but in the absence of other exogenous stimuli. 24 h later cell-free culture SN was harvested, aliquotted, end stored at -20oC until used
- T-BMF CD4+ T cell clone
- CD4 + T cell clones were established elsewhere by standard methodologies. The following CD4 + T cell clones were assigned to the Th1 subset on the basis of their secretion of ⁇ L-2 and IFN-g, but not IL-4: The rabbit gamma globulin-specific,
- Th1 clone Ia d -restricted Th1 clone, D1.6, was established in the laboratory of Dr. Abul Abbas (Harvard Medical School, Boston, MA) whereas the KLH-specific Th1 clones, RA1, RA5, RA8, RC5, and RC9 were established at Immunex
- T cell clones were maintained by weekly stimulation with antigen, spleen cells (as a source of antigen-presenting cells [APCs]), and exogenous IL-2.
- Cytokine-containing SN were obtained from cultures of these CD4 + T cell clones in the following manner: Tissue culture wells were incubated with anti-CD3 mAb (2C11) at 10 mg/ml in PBS for 3h at 37°C and then washed 3x in fresh PBS. T cell clones which were allowed to return to their resting state after
- exogenous stimuli were added to anti-CD3-coated plates at 1 ⁇ 10 6 /ml for various times, upon which cell-free SN were obtained and either stored at -20°C or 4°C. In the latter case, SN was used in cellular assays within 1-2 weeks of having been harvested. Cytofluorometric analysis and cell sorting.
- Spleen cells were stained for 30 min with FITC-labelled anti-CD3 mAb + PE-labelled anti-IgM antibodies (final concentration of 10 mg/ml each in the presence of a 5-fold excess of anti-Fc ⁇ RII mAb to prevent cytophilic antibody binding) at 10 7 cells/ml in cold clear HBSS containing 3% FBS and 50 mg/ml each of penicillin, streptomycin, and gentamicin. Cells were then washed and resuspended in staining buffer at 10 7 cells/ml in preparation for fluorescence analysis and/or cell sorting.
- a FACStar Plus or FACSCAN (y Becton Dickinson, Mountainview, CA) was used and 15,000 cells were collected using logarithmic amplification. Only viable cells were analyzed on the basis of their characteristic forward and side scatter profiles, cell sorting was similarly carried out on a FACStar Plus, as well as on an Epics Elite (Coulter Corp., Hialeah, FL), and sorted cells were immediately reanalyzed to confirm their staining profile. Only sorting purities of >98% were acceptable for subsequent study. Sort-purified B cells (mIgM + CD 3- ) were referred to as B sp cells. Non-B, non-T cells (mIgM-CD3-) and T cells (mIgM-CD3 + ) were also collected and macrophages were routinely eliminated, during sorting, on the basis of their characteristic forward and side scatter profile
- IgM concentrations were measured by ELISA, with Immulon 4, 96-well
- Biotinylated anti-IL-6 mAb (MP5-32c11) was used at 1 mg/ml and avidin-conjugated alkaline phosph atase at a dilution of 1/2,000. Preliminary experiments showed this assay to be sensitive to 0.22 ng/ml of rIL-6.
- ⁇ -dex potently induce proliferation of murine B cells in vitro.
- mAbs monoclonal antibodies
- This construct consisted of covalent linkage of multiple anti-IgD monoclonal antibodies (mAbs) to a high molecular weight dextran backbone.
- mAbs monoclonal antibodies
- ⁇ -dex Ref 1
- the high valency of anti-IgD antibodies linked to dextran resulted in extensive B cell mlg crosslinkage at extremely low concentrations of anti-IgD. This resulted in minimal modulation of mlgD from the B cell surface and hence allowed for continuous B cell signalling.
- ⁇ -dex induced resting murine splenic B cells to proliferate but did not, by itself, stimulate Ig secretion. Compared to unconjugated anti-IgD, ⁇ -dex induced substantially higher maximal levels of
- ⁇ -dex represented the first efficient in vitro system for inducing cytokine-dependent polyclonal Ig secretion through the mlg signal transduction pathway.
- the population of small, resting B cells utilized in these studies were established by depleting T lymphocytes from spleen cells with a cocktail of anti-T cell antibodies and complement followed by fractionation, according to density, by centrifugation on a
- IL-2 stimulated Ig secretion by ⁇ -dex-activated B c cells but not by highly purified B cells.
- IL-2 or IL-5 could act directly on the ⁇ -dex-activated B cell to induce Ig secretion we obtained a highly purified population of small B cells through the use of a florescence activated electronic cell sorter (FACS) (Fig 1).
- FACS florescence activated electronic cell sorter
- small B e cells were stained with phycoerythrin (PE)-labelled anti-IgM antibody which selectively binds to mIgM + B cells, plus FITC-anti-CD3 to identify and eliminate any residual T cells and/or cells binding anti-IgM non-specifically.
- Sort-purified mIgM + B cells were obtained at >99% purity and are henceforth referred to as B sp cells.
- non-T cells responsible for induction of Ig secretion in ⁇ -dex plus IL-2-activated B sp cells are AsGm-1 + -Depletion of macrophages from the B e cell population, by exploiting the property of macrophages to selectively adhere to plastic, had no effect on Ig secretion in ⁇ -dex plus IL-2 activated B e cells (data not shown).
- the non-B, non-T cell necessary for induction of Ig secretion in this system was an NK cell. Since the vast majority of splenic NK cells, as well as some
- NK cells selectively express the marker Asialo Gm-1 (AsGm-1) on their surface, we eliminated NK cells by incubating small B e cells with anti-AsGm-1 antibody plus complement. This procedure abrogated the Ig secretory response of B e cells to ⁇ -dex plus IL-2 strongly suggesting that NK cells were responsible for induction of Ig secretion in this system (Fig 3).
- AsGm-1 Asialo Gm-1
- mice which were homozygous for the severe combined immunodeficiency (scid) mutation.
- Such mice genetically lack both B and T cells but contain functional NK cells.
- Culture of scid spleen cells in relatively high concentrations of IL-2 resulted, within 6 days, in a pure population of activated NK cells as demonstrated by flow cytometric analysis (Fig 4).
- Fig 4 flow cytometric analysis
- IL-2-activated B sp cells resulted in induction of Ig secretion which was comparable to that observed when sort-purified splenic non-B, non-T cells were added (Fig 5).
- Sort-purified small naive splenic T cells by contrast, were ineffective at inducing Ig secretion in this system.
- NK cells induced optimal Ig secretion when present at 5-10% of the B cell population (Fig 6).
- IL-2-activated NK cell cultures also induced Ig secretion in ⁇ -dex plus IL-2-activated B sp cells in the absence of NK cells indicating that NK cells released a BMF (Table 2).
- NK-BMF Activated BMF
- Optimal Ig induction by NK-BMF occured at 50% final volume of NK-BMF with little if any activity observed at 10% (Fig 7).
- NK-BMF is not among the cytokines known to induce B cell activation and maturation.
- NK-BMF NK-BMF was among the cytokines known to induce B cell activation and differentiation.
- cytokines either singly or in combination, at various concentrations, to cultures of B sp cells stimulated with ⁇ -dex plus IL-2.
- IL-3 , IL-4, IL-10, TNF- ⁇ , IFN- ⁇ , lFN- ⁇ / ⁇ , GM-CSF, or TGF- ⁇ was capable of inducing Ig secretion in this system.
- TGF- ⁇ TGF- ⁇ was capable of inducing Ig secretion in this system.
- Anti-CD3-activated murine CD4 + T cell clones also release a BMF. Studies with NK-BMF indicated that this activity was present at relatively low titers as
- CD3 is a component of the T cell antigen-receptor and its crosslinkage induces T cell activation.
- CD4 + T cell clones have been subdivided into two broad
- Th1 clones exclusively release IL-2, IFN- ⁇ and lymphotoxin upon activation whereas Th2 clones exclusively release IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13. Both types of Th clones share the ability to release TNF- ⁇ , IL-3, and GM-CSF. Since we demonstrated that IL-5, present
- Th1 clones exclusively in SN from anti-CD3-activated Th2 clones, could induce Ig secretion by ⁇ -dex or ⁇ -dex plus IL-2-activated B sp cells we evaluated Th1 clones for their potential release of a novel BMF.
- Th1 clones were found to release BMF (Fig 8).
- This BMF is henceforth referred to as T-BMF.
- T-BMF In contrast to NK-BMF which was required at a 25-50% final volume to induce Ig secretion, T-BMF induced near-optimal Ig secretion at a final volume of 0.1% and continued to have Ig-inducing activity at 0.01% (Fig 9).
- BMF-containing T cell supernatants appeared to be at least 250-fold more potent in
- T-BMF Ig-inducing activity than supernatants derived from activated NK cell cultures.
- T-BMF in the absence of ⁇ -dex+IL-1+IL-2, had no Ig-inducing effect on small B sp cells (data not shown).
- T-BMF is a protein and is not among the cytokines known to induce B cell activation and differentiation. That T-BMF is a protein was demonstrated by the ability of proteinase K treatment to abrogate the Ig-inducing activity of T-BMF (Fig 10).
- T-BMF was not IL-6 as indicated in two distinct ways: (1) direct measurement of IL-6 in T-BMF, utilizing a highly sensitive ELISA, indicated undetectable amounts of IL-6 ( ⁇ 200 pg/ml) in undiluted T-BMF (Fig 11). since T-BMF induces Ig at 0.01% final volume, IL-6 if present would be ⁇ 0.02 pg/ml. Since IL-6 has been reported to exhibit B cell maturation effects only at concentrations in the ng/ml range, it is highly unlikely that T-BMF was IL-6. (2) Addition of IL-6 from 2-20,000 pg/ml to cultures of ⁇ -dex plus IL-2-activated B sp cells failed to induce Ig secretion (Table 5). Finally, since TNF- ⁇ and
- T-BMF lymphotoxin binds to the same receptor and exhibit nearly overlapping functional effects, it is highly unlikely that T-BMF is lymphotoxin, since TNF- ⁇ is not active as a BMF in this system.
- T-BMF is released early after anti-CD3-activation of a Th1 clone-Kinetic studies were performed to determine the time during which T-BMF was induced upon activation with anti-CD3 mAb. Approximately 90% of total T-BMF activity was induced between 2-3 h after anti-CD3 activation (Fig 12). m the absence of anti-CD3 no detectable BMF was induced in the Th1 clone,
- T-BMF acts late in culture to stimulate Ig secretion by ⁇ -dex plus IL-1+IL-2-activated B cells.
- T-BMF acts late in culture to stimulate Ig secretion by B cells activated with ⁇ -dex plus IL-1+IL-2.
- T-BMF strongly induced IG secretion, even when it was added as late as day 3 of the 6 day culture and the level of T-BMF-induced Ig secretion was
- T-BMF acts late in culture to induce Ig secretion, supporting the view that it functions as a true B cell maturation factor.
- T-BMF induced opitmal Ig secretion when its addition to culture was delayed by 2 days suggests that either T-BMF or a separate component in the T cell SN in inhibitory for Ig secretion when present early in culture, or that T-BMF activity progressively declines during the culture period and is not available in optimal amounts, when added at initiation of culture, for inducing Ig secretion late in culture.
- B e and B sp cells were cultured at 1.25 X 10 5 cells/ml in the presence of ⁇ -dex (3 ng/ml), IL-2 (150 U/ml), IL-5 (150 U/ml) and/or LPS (20 ⁇ g/ml).
- ⁇ -dex 3 ng/ml
- IL-2 150 U/ml
- IL-5 150 U/ml
- LPS 20 ⁇ g/ml
- B e and B sp cells were cultured at 1.25 X 10 5 cells/ml in the presence of ⁇ -dex (3 ng/ml), IL-1 (150 U/ml), IL-2 (150 U/ml), IL-5 (150 U/ml), NK-BMF (25% v/v), and/or T-BMF (25% v/v).
- SN was harvested for determination of secreted IgM concentrations by ELISA. Table 3
- B e cells were cultured at 1.0 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml), IL-1 (100 U/ml and IL-2 (150 U/ml) in the absence or presence of the following antibodies: (1) anti-TNF- ⁇ mAb (XT22; 50 g/ml), (2) anti-IFN ⁇ mAb (XMG-6; 50 ⁇ g/ml), (3) polyclonal rabbit anti-IFNa/B anti-serum (1/50 v/v), (4) anti-IL-4 mAb (11b11; 50 ⁇ g/ml), (5) anti-IL-5 mAb (TRFK-5; 50 ⁇ g/ml), (6) anti-IL-6 mAb (P7; 50 ⁇ g/ml), and (7) anti-IL-10 mAb (SXC; 20 ⁇ g/ml).
- B sp cells were cultured at 1.5 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml), IL-1 (100 U/ml) and IL-2 (150 U/ml) in the absence or presence of the.
- cytokines (1) IL-3 (WEHI 3 SN 25% v/v), (2) rIL-4 (1000 U/ml), (3) rIL-10 (10 U/ml), 4) rTNF ⁇ (100 U/ml), (5) rIFN ⁇ (10 U/ml), (6) rIFNa (100 U/ml), (7) rGM-CSF (100 U/ml), and/or (8) purified natural TGF- ⁇ 1 (1.0 ng/ml).
- IL interleukin
- TNF tumor necrosis factor
- IFN interferon
- GM-CSF granulocyte-macrophage colony stimulating factor
- TGF transforming growth factor
- B sp cells were cultured at 1.5 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml), IL-1 (150 U/ml), IL-2 (150 U/ml) and/or T-BMF (0.1% v/v [24 hr SN from anti-CD3-activated RA5 Th1 clone]) in the absence or presence of the following antibodies/antagonists: [A] (1) anti-IFN- ⁇ mAb (XMG-6; 10 ⁇ g/ml), (2) TNFRIg (10 ⁇ g/ml;
- TNFRIg tumor necrosis factor receptor-Ig hybrid molecule which binds and neutralizes free TNF- ⁇
- anti-GM-CSF mAb 10 ⁇ g/ml/ purchased from Genzyme
- anti-IL-3 mAb 8F8.1, 10 ⁇ g/ml
- anti-IL-4 mAb 11B11; 10 ⁇ g/ml
- anti-IL-5 mAb TRFK-5; 10 g/ml
- anti-IL-10 mAb (2A5; 10 ⁇ g/ml)
- huCD40Fc (10 ⁇ g/ml; [human recombinant CD40-lg hybrid with binds and neutralizes free CD40 ligand).
- anti-IL-6 mAG MP 520 Pc; 10 ⁇ g/ml
- SN was harvested for determination of secreted IgM concentrations by ELISA.
- B sp cells were cultured at 1.5 ⁇ 10 5 cells/ml with ⁇ -dex (3 ng/ml), IL-1 (150 U/ml), in the absence or presence of various concentrations of rIL-6 (1-10,000 U/ml) and/or T-BMF (1.0% v/v [24 hr SN from anti-CD3-activated RA5 Th1 clone]). Sic days after initiation of culture, SN was harvested for
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7513935A JPH09505285A (en) | 1993-11-10 | 1994-11-08 | Natural killer cell or T cell-derived cytokine |
EP95901809A EP0726913A4 (en) | 1993-11-10 | 1994-11-08 | Cytokines from natural killer or t cells |
AU10908/95A AU1090895A (en) | 1993-11-10 | 1994-11-08 | Cytokines from natural killer or t cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15051093A | 1993-11-10 | 1993-11-10 | |
US08/150,510 | 1993-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995013294A1 true WO1995013294A1 (en) | 1995-05-18 |
Family
ID=22534880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/012835 WO1995013294A1 (en) | 1993-11-10 | 1994-11-08 | Cytokines from natural killer or t cells |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0726913A4 (en) |
JP (1) | JPH09505285A (en) |
AU (1) | AU1090895A (en) |
CA (1) | CA2176114A1 (en) |
WO (1) | WO1995013294A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
-
1994
- 1994-11-08 JP JP7513935A patent/JPH09505285A/en active Pending
- 1994-11-08 EP EP95901809A patent/EP0726913A4/en not_active Withdrawn
- 1994-11-08 AU AU10908/95A patent/AU1090895A/en not_active Abandoned
- 1994-11-08 WO PCT/US1994/012835 patent/WO1995013294A1/en not_active Application Discontinuation
- 1994-11-08 CA CA002176114A patent/CA2176114A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
CELLULAR IMMUNOLOGY, Volume 146, No. 2, issued 1993, PATEL et al., "Stimulus-Dependent Modulation of Human B Cell Function by T Cell Clones", pages 362-381. * |
EUROPEAN JOURNAL OF IMMUNOLOGY, Volume 20, issued 1990, AMIGORENA et al., "Recombinant Interleukin 2-Activatd Natural Killer Cells Regulate IgG2a Production", pages 1781-1787. * |
See also references of EP0726913A4 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US9714283B2 (en) | 2014-10-28 | 2017-07-25 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US9969793B2 (en) | 2014-10-28 | 2018-05-15 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US10683343B2 (en) | 2014-10-28 | 2020-06-16 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US11339206B2 (en) | 2014-10-28 | 2022-05-24 | Adma Biomanufacturing, Llc | Compositions and methods for the treatment of immunodeficiency |
US11780906B2 (en) | 2014-10-28 | 2023-10-10 | Adma Biomanufacturing, Llc | Compositions and methods for the treatment of immunodeficiency |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
US11084870B2 (en) | 2017-03-15 | 2021-08-10 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
US11897943B2 (en) | 2017-03-15 | 2024-02-13 | Adma Biomanufacturing, Llc | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
Also Published As
Publication number | Publication date |
---|---|
EP0726913A1 (en) | 1996-08-21 |
AU1090895A (en) | 1995-05-29 |
JPH09505285A (en) | 1997-05-27 |
EP0726913A4 (en) | 2000-01-26 |
CA2176114A1 (en) | 1995-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Snapper et al. | IFN-gamma stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. | |
Ishida et al. | Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. | |
Pene et al. | IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. | |
Openshaw et al. | Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. | |
te Velde et al. | Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes | |
Limaye et al. | Regulation of parasite-induced eosinophilia: selectively increased interleukin 5 production in helminth-infected patients. | |
Murphy et al. | Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. | |
Rousset et al. | Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4 | |
Thyphronitis et al. | IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin 4 and suppressed by interferon gamma. | |
Parronchi et al. | Allergen-and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. | |
Beagley et al. | Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. | |
Kishimoto | B-cell stimulatory factors (BSFs): molecular structure, biological function, and regulation of expression | |
Katsikis et al. | Immunoregulatory role of interleukin 10 in rheumatoid arthritis. | |
Snapper et al. | Natural killer cells induce activated murine B cells to secrete Ig. | |
Brinkmann et al. | TCR-stimulated naive human CD4+ 45RO-T cells develop into effector cells that secrete IL-13, IL-5, and IFN-gamma, but no IL-4, and help efficient IgE production by B cells. | |
Fischer et al. | Cytokine production by mature and immature thymocytes. | |
EP0505397B1 (en) | Method of making factor-dependent human b cell lines | |
Smyth et al. | IL-7 regulation of cytotoxic lymphocytes: pore-forming protein gene expression, interferon-γ production, and cytotoxicity of human peripheral blood lymphocyte subsets | |
Vicari et al. | NK1. 1+ T cells from IL-7-deficient mice have a normal distribution and selection but exhibit impaired cytokine production | |
Keegan et al. | Superinduction of the murine B cell Fc epsilon RII by T helper cell clones. Role of IL-4. | |
Quint et al. | Functional and phenotypic analysis of human T-cell clones which stimulate IgE production in vitro. | |
Acres et al. | Production of IL-1α and IL-1β by clones of EBV transformed, human B cells | |
Snapper et al. | IL-3 and granulocyte-macrophage colony-stimulating factor strongly induce Ig secretion by sort-purified murine B cell activated through the membrane Ig, but not the CD40, signaling pathway. | |
Pecanha et al. | IL-10 inhibits T cell-independent but not T cell-dependent responses in vitro. | |
Pistoia et al. | Relationships between B cell cytokine production in secondary lymphoid follicles and apoptosis of germinal center B lymphocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2176114 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995901809 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995901809 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995901809 Country of ref document: EP |